Artin Moussavi

Leucid Bio Ltd. is a clinical-stage biotechnology company based in London, UK. The British company develops novel, lateral car cell therapies for the treatment of refractory cancers, with a focus on developing next-generation cell therapies for the benefit of individuals with hard-to-treat solid tumors. The company's operations are based at Guys Hospital, enabling them to maintain a patient-centric focus. Leucid's goal is to develop CAR-T therapies with more durable responses, improving treatment outcomes and saving the lives of patients with refractory cancers. Leucid was established to translate 20 years of Kings College research in the CAR-T field and is led by a highly experienced management team, including scientific founder John Maher. Filippo Joseph Petti has been the CEO of the company since 2023.

Lux Biotechnology Ltd. develops light based detection technology. It has ongoing co-development projects in the energy, chemical, water, and life science sectors with potential application development in many more. Its products include Glowel, a series of novel and light standards for the calibration of scientific equipment. The company was founded by Patrick Hickey in 2001 and is headquartered in Edinburgh, UK.

LUX Assure Ltd. provides technology solutions to monitor difficult-to-detect chemicals used by the oil industry. Its offers CoMic a technology that enables optimization of chemicals used for corrosion protection and OMMICA a testing kit for analyzing the concentration of the thermodynamic hydrate inhibitors methanol and monoethylene glycol in water, crude oil, and condensate. The company was founded by Patrick Hickey on May 30, 2001 and is headquartered in Edinburgh, the United Kingdom.